Back to today’s briefing

Story perspectives

Incyte and Genesis Partner to Transform Drug Discovery

2/21/2025

32 3

Summary

Story summary

Incyte Corp. is joining forces with Genesis Therapeutics to revolutionize drug discovery through small molecule medicines, powered by Genesis' cutting-edge AI platform, GEMS. With an initial investment of $30 million and potential earnings of up to $295 million per target, this partnership aims to tackle severe diseases by combining their strengths in oncology and immunology.

1 of 1

Story summary

Incyte Corp. is joining forces with Genesis Therapeutics to revolutionize drug discovery through small molecule medicines, powered by Genesis' cutting-edge AI platform, GEMS. With an initial investment of $30 million and potential earnings of up to $295 million per target, this partnership aims to tackle severe diseases by combining their strengths in oncology and immunology.